[Comparative efficacy of single Berodual inhalation in patients with bronchial asthma: nebulization against dose-adjusted aerosol].

The trial included 34 patients with moderate non-atopic asthma in exacerbation. After arrest of the acute attack the patients inhaled berodual via nebulizer (a single dose of 0.5 ml -125 micrograms ipratropium bromide and 250 micrograms phenoterol) or aerosol (40 micrograms ipratropium and 100 micrograms phenoterol). As shown by body plethysmography and peak-flowmetry, nebulizer therapy was characterized by earlier onset of broncholytic effect which stood longer, more pronounced effect at the level of small and middle bronchi, absence of side effects. The authors believe that berodual inhalations through nebulizer are an effective modality in the treatment of bronchial asthma in severe exacerbation.